FULCRUM THERAPEUTICS INC (FULC)       7.28  -0.54 (-6.91%)

7.28  -0.54 (-6.91%)

US3596161097 - Common Stock - After market: 7.49 +0.21 (+2.88%)

News Image
14 hours ago - Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics® to Participate at the Upcoming Stifel 2022 Biotech Summer Summit

CAMBRIDGE, Mass., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on...

News Image
a day ago - Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics Announces Pricing of Public Offering of Common Stock

CAMBRIDGE, Mass., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on...

News Image
a day ago - Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics Announces Proposed Public Offering of Common Stock

CAMBRIDGE, Mass., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on...

News Image
6 days ago - Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics Announces Second Quarter 2022 Financial Results and Business Update

Presented initial data from Phase 1b trial in sickle cell disease (SCD), which demonstrate rapid and robust increases in hemoglobin F (HbF); supports...

News Image
13 days ago - Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics® to Host Second Quarter 2022 Financial Results Conference Call and Webcast on Thursday, August 11, 2022 at 8:00 a.m. ET

CAMBRIDGE, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on...

News Image
a month ago - Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., July 15, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on...

News Image
a month ago - Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics Announces Departure of Chief Medical Officer

CAMBRIDGE, Mass., July 11, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on...

News Image
a month ago - Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics Enrolls First Patient in Pivotal Global Phase 3 Clinical Trial of Losmapimod for Facioscapulohumeral Muscular Dystrophy (FSHD)

– REACH is the first Phase 3 trial for this rare, progressive, and debilitating muscular disease –– Losmapimod is an oral small molecule that has the...

News Image
2 months ago - Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., June 10, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on...

News Image
2 months ago - Market News Video

Friday Sector Laggards: Biotechnology, Drugs

News Image
2 months ago - Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics Announces Proof-of-Concept for FTX-6058 in Sickle Cell Disease Based on Initial Data from the Ongoing Phase 1b Trial

- Achieved up to 6.3% hemoglobin F (HbF) induction in initial subjects in first cohort; HbF was increasing at last measured timepoint - Supports...

News Image
3 months ago - Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics to Present Initial Data from Phase 1b Trial of FTX-6058 in Adults Living with Sickle Cell Disease at the European Hematology Association (EHA) Hybrid Congress in Vienna, Austria

- FTX-6058 is the only oral hemoglobin F (HbF) inducer in clinical development -Data will include initial HbF changes, safety, tolerability,...

News Image
3 months ago - Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics Reports Recent Business Highlights and First Quarter 2022 Financial Results

– Initial data from Phase 1b trial of FTX-6058 in sickle cell disease to be presented at the EHA 2022 Congress – – Phase 3 REACH trial of losmapimod...

News Image
3 months ago - Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., May 06, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on...

News Image
3 months ago - Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics to Participate at the Upcoming BofA Securities 2022 Healthcare Conference

CAMBRIDGE, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on...